The Europe Diabetes Care Devices Market would witness market growth of 5.3% CAGR during the forecast period (2022-2028).
Bluetooth-enabled insulin pens have recently improved diabetic technology by allowing users to record the dose and time of injection. Furthermore, some of these smartpens come with built-in bolus calculators to aid in insulin dose calculations. They also give clinicians or patients downloadable data reports. Clinicians have previously adjusted insulin administration based on blood glucose monitoring records and the assumption that patients are taking their insulin as recommended (both timing and dose). Omissions or errors in insulin doses and timing are prevalent in diabetic individuals who need repeated insulin injections. In a recent study by the National Library of Medicines, Bluetooth-enabled insulin pens were demonstrated to capture variance from insulin prescriptions in persons with T1D or T2D on insulin injection. In this study, 22% of the older subgroup showed noncompliance with bolus insulin dose, whereas 27% showed noncompliance with basal insulin administration. Nonadherence as determined by these approaches was also linked to poor glycemic control, according to the findings.
Diabetes is becoming more common among people of all ages in Europe, owing to rising rates of overweight and obesity, poor diet, and physical inactivity. According to the World Health Organization, people with diabetes die from cardiovascular disease (mainly heart disease and stroke) in 50% of cases, and kidney failure in 10-20% of cases. In the European Region, around 60 million people have diabetes, accounting for 10.3% of men and 9.6% of women aged 25 and over. Additionally, according to the International Diabetes Federation (IDF), diabetes has reached 15.3% in Germany. This is a 25% increase over the previous year's rate (12.2%), according to the organization. In Germany, an estimated 9.5 million adults have diabetes, putting them at risk of life-threatening complications.
4.5 million of the 9.5 million people are undiagnosed, putting them at a higher risk. These frightening statistics highlight the urgent need to implement Germany's national diabetes plan, which was stipulated in the 2018 coalition treaty. Diabetes affects 3.9 million people in the United Kingdom. In addition, it is expected to affect five million people in the UK by 2025. As a result of the increased prevalence of diabetes, people are focusing on controlling their blood glucose levels, necessitating the use of insulin syringes. Due to the increasing demand for syringes along with the higher prevalence of diabetes in the region, the regional market is witnessing an accelerated growth.
The Germany market dominated the Europe Diabetes Care Devices Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,847.8 Million by 2028. The UK market is anticipated to grow at a CAGR of 4.4% during (2022 - 2028). Additionally, The France market would showcase a CAGR of 6.1% during (2022 - 2028).
Based on Product, the market is segmented into Insulin Delivery Devices and Blood Glucose Monitoring Devices. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Diabetes Care Devices Market Size will Hit $29.3 Billion by 2028, at a CAGR of 6.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., DexCom, Inc., Novo Nordisk A/S, Sanofi S.A., Zealand Pharma A/S, B. Braun Melsungen AG, Bayer AG, Abbott Laboratories, Ypsomed AG, Arkray, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Insulin Delivery Devices and
- Blood Glucose Monitoring Devices
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- F. Hoffmann-La Roche Ltd.
- DexCom, Inc.
- Novo Nordisk A/S
- Sanofi S.A.
- Zealand Pharma A/S
- B. Braun Melsungen AG
- Bayer AG
- Abbott Laboratories
- Ypsomed AG
- Arkray, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Diabetes Care Devices Market, by Product
1.4.2 Europe Diabetes Care Devices Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.2.5 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements : 2018, Oct – 2022, May) Leading Players
Chapter 4. Europe Diabetes Care Devices Market by Product
4.1 Europe Insulin Delivery Devices Market by Country
4.2 Europe Blood Glucose Monitoring Devices Market by Country
Chapter 5. Europe Diabetes Care Devices Market by Country
5.1 Germany Diabetes Care Devices Market
5.1.1 Germany Diabetes Care Devices Market by Product
5.2 UK Diabetes Care Devices Market
5.2.1 UK Diabetes Care Devices Market by Product
5.3 France Diabetes Care Devices Market
5.3.1 France Diabetes Care Devices Market by Product
5.4 Russia Diabetes Care Devices Market
5.4.1 Russia Diabetes Care Devices Market by Product
5.5 Spain Diabetes Care Devices Market
5.5.1 Spain Diabetes Care Devices Market by Product
5.6 Italy Diabetes Care Devices Market
5.6.1 Italy Diabetes Care Devices Market by Product
5.7 Rest of Europe Diabetes Care Devices Market
5.7.1 Rest of Europe Diabetes Care Devices Market by Product
Chapter 6. Company Profiles
6.1 F. Hoffmann-La Roche Ltd.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Product Launches and Product Expansions:
6.2 DexCom, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Regional Analysis
6.2.4 Research & Development Expenses
6.2.5 Recent strategies and developments:
6.2.5.1 Partnerships, Collaborations, and Agreements:
6.2.5.2 Product Launches and Product Expansions:
6.2.5.3 Acquisition and Mergers:
6.3 Novo Nordisk A/S
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental & Regional Analysis
6.3.4 Research & Development Expenses
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.3.5.2 Acquisition and Mergers:
6.4 Sanofi S.A.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Product Launches and Product Expansions:
6.5 Zealand Pharma A/S (Valeritas, Inc.)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Research & Development Expenses
6.5.4 Recent strategies and developments:
6.5.4.1 Product Launches and Product Expansions:
6.5.4.2 Approvals and Trials:
6.6 B. Braun Melsungen AG
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.6.5 Recent strategies and developments:
6.6.5.1 Partnerships, Collaborations, and Agreements:
6.7 Bayer AG
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Partnerships, Collaborations, and Agreements:
6.7.5.2 Approvals:
6.8 Abbott Laboratories
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Partnerships, Collaborations, and Agreements:
6.8.5.2 Approvals:
6.9 Ypsomed AG
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Recent strategies and developments:
6.9.4.1 Partnerships, Collaborations, and Agreements:
6.10. Arkray, Inc.
6.10.1 Company Overview
6.10.2 Recent strategies and developments:
6.10.2.1 Partnerships, Collaborations, and Agreements:
6.10.2.2 Geographical Expansions:
TABLE 1 Europe Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 2 Europe Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Diabetes Care Devices Market
TABLE 4 Product Launches And Product Expansions– Diabetes Care Devices Market
TABLE 5 Acquisition and Mergers– Diabetes Care Devices Market
TABLE 6 Geographical expansion– Diabetes Care Devices Market
TABLE 7 Approvals and Trials– Diabetes Care Devices Market
TABLE 8 Europe Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 9 Europe Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 10 Europe Insulin Delivery Devices Market by Country, 2018 - 2021, USD Million
TABLE 11 Europe Insulin Delivery Devices Market by Country, 2022 - 2028, USD Million
TABLE 12 Europe Blood Glucose Monitoring Devices Market by Country, 2018 - 2021, USD Million
TABLE 13 Europe Blood Glucose Monitoring Devices Market by Country, 2022 - 2028, USD Million
TABLE 14 Europe Diabetes Care Devices Market by Country, 2018 - 2021, USD Million
TABLE 15 Europe Diabetes Care Devices Market by Country, 2022 - 2028, USD Million
TABLE 16 Germany Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 17 Germany Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 18 Germany Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 19 Germany Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 20 UK Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 21 UK Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 22 UK Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 23 UK Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 24 France Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 25 France Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 26 France Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 27 France Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 28 Russia Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 29 Russia Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 30 Russia Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 31 Russia Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 32 Spain Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 33 Spain Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 34 Spain Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 35 Spain Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 36 Italy Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 37 Italy Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 38 Italy Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 39 Italy Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 40 Rest of Europe Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 41 Rest of Europe Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 42 Rest of Europe Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 43 Rest of Europe Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 44 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 45 Key Information – DexCom, Inc.
TABLE 46 Key information – Novo Nordisk A/S
TABLE 47 Key Information – Sanofi S.A.
TABLE 48 Key Information – Zealand Pharma A/S
TABLE 49 key Information – B. Braun Melsungen AG
TABLE 50 Key Information – Bayer AG
TABLE 51 Key Information – Abbott Laboratories
TABLE 52 Key Information –-Ypsomed AG
TABLE 53 Key Information – Arkray, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
FIG 4 Key Strategic Move: (Partnerships, collaborations and agreements : 2018, oct – 2022, may) Leading Players
FIG 5 Recent strategies and developments: F. Hoffmann-La Roche Ltd.
FIG 6 Recent strategies and developments: DexCom, Inc.
FIG 7 Recent strategies and developments: Novo Nordisk A/S
FIG 8 Recent strategies and developments: Sanofi S.A.
FIG 9 Recent strategies and developments: Zealand Pharma A/S
FIG 10 Recent strategies and developments: Arkray, Inc.